This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4 – 10 December 2022 and includes updates on COVID-19, Ebola virus, respiratory syncytial virus, streptococcal infection, diphtheria, seasonal influenza, mpox (monkeypox), hepatitis, MERS-CoV, meningitis, and mass gathering monitoring at the FIFA World Cup 2022 Qatar.
The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
For 2020, 29 EU/EEA Member States reported 14 428 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases (14 137) corresponds to a crude rate of 4.2 cases per 100 000 population.
In 2020, 13 914 cases of hepatitis C were reported in 28 EU/EEA Member States. Excluding countries that only reported acute cases leaves 13 901 cases, which corresponds to a crude rate of 3.9 cases per 100 000 population.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.